Safety and Tolerability of Alveolar Type II Cell Transplantation in Idiopathic Pulmonary Fibrosis

Chest

Volumn 150, Issue 3, 2016, Pages 533-543

  Serrano Mollar, Anna ^a,b   Gay Jordi, Gemma ^a,b   Guillamat Prats, Raquel ^a,b   Closa, Daniel ^a   Hernandez Gonzalez, Fernanda ^a,b   Marin, Pedro ^c   Burgos, Felip ^b   Martorell, Jaume ^c   Sánchez, Marcelo ^c   Arguis, Pedro ^c   Soy, Dolors ^b,c,d   Bayas, José M ^c   Ramirez, José ^b,c,e   Tetley, Teresa D ^f   Molins, Laureano ^c,d   de la Bellacasa, Jordi Puig ^c,d   Rodríguez Villar, Camino ^c   Rovira, Irene ^c   Fiblà, Juan José ^e   Xaubet, Antoni ^b,d  

^a INST D INVESTIGACIONS B   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e HOSPITAL UNIVERSITARI SAGRAT COR   (Spain)

^f NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

alveolar type II cells; cell therapy; idiopathic pulmonary fibrosis

Indexed keywords

AZITHROMYCIN; PREDNISONE; ANTIINFECTIVE AGENT; CORTICOSTEROID; COTRIMOXAZOLE; FOLINIC ACID; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; NYSTATIN; TACROLIMUS; VALGANCICLOVIR;

ADULT; AGED; ALVEOLAR ARTERIAL OXYGEN PARTIAL PRESSURE; ALVEOLAR TYPE II CELL INTRATRACHEAL TRANSPLANTATION; ANTIBIOTIC THERAPY; ARTICLE; BRONCHITIS; CELL TRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DISEASE COURSE; DISEASE SEVERITY; DYSPNEA; FEMALE; FIBEROPTIC BRONCHOSCOPY; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HUMAN CELL; HYPERGLYCEMIA; HYPOXEMIA; IMMUNOSUPPRESSIVE TREATMENT; LEG CRAMP; LUNG INFILTRATE; MALE; OXYGEN SATURATION; PRIORITY JOURNAL; RASH; RESPIRATORY TRACT DISEASE; SINGLE BREATH DIFFUSING CAPACITY FOR CARBON MONOXIDE; SINGLE DRUG DOSE; WALKING SPEED; ANALOGS AND DERIVATIVES; BACTERIAL INFECTIONS; BRONCHOSCOPY; DIAGNOSTIC IMAGING; GRAFT REJECTION; IDIOPATHIC PULMONARY FIBROSIS; LUNG ALVEOLUS EPITHELIUM CELL; LUNG DIFFUSION CAPACITY; MIDDLE AGED; MYCOSES; PATHOPHYSIOLOGY; PROCEDURES; TRACHEA; TRANSPLANTATION; TREATMENT OUTCOME; VIRUS DISEASES; VITAL CAPACITY; WALK TEST;

ADRENAL CORTEX HORMONES; AGED; ALVEOLAR EPITHELIAL CELLS; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; BRONCHOSCOPY; CELL TRANSPLANTATION; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; GANCICLOVIR; GRAFT REJECTION; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; IMMUNOSUPPRESSIVE AGENTS; LEUCOVORIN; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; MYCOSES; NYSTATIN; PULMONARY DIFFUSING CAPACITY; TACROLIMUS; TRACHEA; TREATMENT OUTCOME; TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION; VIRUS DISEASES; VITAL CAPACITY; WALK TEST;

EID: 84995685397     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2016.03.021     Document Type: Article

References (27)

1. 1 Raghu, G., Collard, H.R., Egan, J.J., et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:6 (2011), 788–824.
2. 2 Katzenstein, A.A., Myers, J.L., Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. State of the art. Am J Resp Crit Care Med 157:4 Pt 1 (1998), 1301–1315.
3. 3 Phan, S.H., Biology of fibroblasts and myofibroblasts. Proc Am Thorac Soc 5:3 (2008), 334–337.
4. 4 Wynes, M.W., Edelman, B.L., Kostyk, A.G., et al. Increased cell surface Fas expression is necessary and sufficient to sensitize lung fibroblasts to Fas ligation-induced apoptosis: implications for fibroblast accumulation in idiopathic pulmonary fibrosis. J Immunol 187:1 (2011), 527–537.
5. 5 Serrano-Mollar, A., Nacher, M., Gay-Jordi, G., et al. Intratracheal transplantation of alveolar type II cells reverses bleomycin-induced lung fibrosis. Am J Respir Crit Care Med 176:12 (2007), 1261–1268.
6. 6 Guillamat-Prats, R., Gay-Jordi, G., Xaubet, A., et al. Alveolar type II cell transplantation restores pulmonary surfactant protein levels in lung fibrosis. J Heart Lung Transplant 33:7 (2014), 758–765.
7. 7 Serrano-Mollar A, Closa D, Bulbena O, inventors. Use of type II pneumocytes in the treatment of pulmonary diseases associated with pulmonary fibrosis. Patent-Granted: Canadian patent CA 2631172 (August 5, 2014), European patent EP 1961423 (May 21, 2012), based on Spanish priority patent ES 200502939 (November 28, 2005).
8. 8 Noble, P.W., Albera, C., Bradford, W.Z., et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 377:9779 (2011), 1760–1769.
9. 9 Flaherty, K.R., Andrei, A.C., Murray, S., et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med 174:7 (2006), 803–809.
10. 10 du Bois, R.M., Weycker, D., Albera, C., et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 184:12 (2011), 1382–1389.
11. 11 Danzinger-Isakov, L., Kumar, D., AST Infectious Diseases Community of Practice. Guidelines for vaccination of solid organ transplant candidates and recipients. Am J Transplant 9:suppl 4 (2009), S258–S262.
12. 12 Xaubet, A., Agustí, C., Luburich, P., et al. Pulmonary function tests and CT scan in the management of idiopathic pulmonary fibrosis. Am J Crit Care Med 158:2 (1998), 431–436.
13. 13 Jaeger, C., Brendel, M.D., Hering, B.J., et al. Progressive islet graft failure occurs significantly earlier in autoantibody-positive than in autoantibody-negative IDDM recipients of intrahepatic islet allografts. Diabetes 46:11 (1997), 1907–1910.
14. 14 Shapiro, A.M., Ricordi, C., Hering, B.J., et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 355:13 (2006), 1318–1330.
15. 15 Karpinski, M., Pochinco, D., Dembinski, I., et al. Leukocyte reduction of red blood cell transfusions does not decrease allosensitization rates in potential kidney transplant candidates. J Am Soc Nephrol 15:3 (2004), 818–824.
16. 16 European Medicines Agency. Advagraf product information. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000712/WC500022234.pdf. Accessed May 11, 2016.
17. 17 du Bois, R.M., Weycker, D., Albera, C., et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184:4 (2011), 459–466.
18. 18 Best, A.C., Meng, J., Lynch, A.M., et al. Idiopathic pulmonary fibrosis: physiologic test, quantitative CT indexes, and CT visual scores as predictors of mortality. Radiology 246:3 (2008), 935–940.
19. 19 Spagnolo, P., Wells, A.U., Collard, H.R., Pharmacological treatment of idiopathic pulmonary fibrosis: an update. Drug Discov Today 20 (2015), 514–524.
20. 20 Shulgina, L., Cahn, A.P., Chilvers, E.R., et al. Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomized controlled trial. Thorax 68:2 (2013), 155–162.
21. 21 Richeldi, L., Davies, H.R., Ferrara, G., et al. Corticosteroids for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev(3), 2003, CD002880.
22. 22 Tzouvelekis, A., Bouros, E., Oikonomou, A., et al. Effect and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis. Pulm Med, 2011, 2011, 849035.
23. 23 Elicker, B.M., Golden, J.A., Ordovas, K.G., et al. Progression of native lung fibrosis in lung transplant recipients with idiopathic pulmonary fibrosis. Respir Med 104:3 (2010), 426–433.
24. 24 Fehrenbach, H., Alveolar epithelial type II cell: defender of the alveolus revisited. Respir Res 2:1 (2001), 33–46.
25. 25 Zoz, D.F., Lawson, W.E., Blackwell, T.S., Idiopathic pulmonary fibrosis: a disorder of epithelial cell dysfunction. Am J Med Sci 341:6 (2011), 435–438.
26. 26 Gower, W.A., Nogee, L.M., Surfactant dysfunction. Paediatr Respir Rev 12:4 (2011), 223–229.
27. 27 Burkhardt, A., Alveolitis and collapse in the pathogenesis of pulmonary fibrosis. Am Rev Respir Dis 140:2 (1989), 513–524.